|
siRNA Delivery to Hard-to-Transfect Cell Types
Traditional lipid-based siRNA transfection reagents exhibit a number of drawbacks, including a limited ability to transfect into a variety of cell types, such as primary, neuronal, differentiated, and non-dividing cells.
Sigma’s N-TER Nanoparticle siRNA Transfection System is based on a peptide transfection reagent specifically designed to bypass these limitations and allow for efficient delivery of siRNAs into these historically recalcitrant eukaryotic cell types.
Benefits of the N-TER Nanoparticle siRNA Transfection System:
- Superior transfection of historically difficult-to-transfect cells, including primary, neuronal, differentiated and non-dividing cells
- Quick delivery of siRNA into cells, with reduced cytotoxicity as compared to lipid-based reagents
- Stable N-TER/siRNA nanoparticles can be stored at –20 °C for up to 1 year
- Simple protocol easily adapted for high-throughput and reverse transfection applications
| Product No. |
Description |
Add to Cart |
| N2913-120UL |
N-TER Nanoparticle siRNA Transfection System |
 |
| N2913-400UL |
N-TER Nanoparticle siRNA Transfection System |
|
| N2913-1ML |
N-TER Nanoparticle siRNA Transfection System |
|
N-TER Quickly Delivers siRNA into Cells
|
Click here to view a list of cell types N-TER has been validated to work with and an overview of the simple protocol for N-TER/siRNA tranfection. |
Selected References
- Morris, M. C. et al. A new peptide vector for the efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 1997, 25, 2730-2736.
- Simeoni, F. et al. Insight into the mechanism of the peptide-based gene delivery system MPG: Implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003, 31, 2717-2724.
- Morris, K. V. et al. Small interfering RNA induced transcriptional gene silencing in human cells. Science 2004, 305, 1289-1291.
- Deshayes, S. et al. On mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochem. Biophys. Acta. 2004, 1667(2), 141-147.
- Langlois, M. A. et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J. Biol. Chem. 2005, 280(17), 16949-16954.
Back to Top
|
)
